S-1: Sharps Technology Inc. Announces Proposed Public Offering of Units

Sharps Technology Inc. plans to offer up to 6,726,457 units, each including common stock and warrants, or pre-funded units as an alternative.

Summary

• Sharps Technology Inc. is proposing a public offering of up to 6,726,457 units.
• Each unit will consist of one share of common stock, one Series A warrant, and one Series B warrant.
• As an alternative, purchasers can opt for pre-funded units, each including a pre-funded warrant, a Series A warrant, and a Series B warrant.
• The assumed public offering price is $2.23 per unit, based on the closing price of the common stock on January 7, 2025.
• The Series A and B warrants have an exercise price of $2.787 per share, which is 125% of the assumed public offering price.
• The Series A warrants expire five years after stockholder approval, while the Series B warrants expire two and a half years after stockholder approval.
• The company intends to use the proceeds for general corporate purposes, including working capital and investments, and to repay $4,174,658 in outstanding senior notes.

Sentiment

Score: 4

Explanation: The document presents a mix of positive and negative aspects. While the company is raising capital and has plans for growth, it also faces significant risks, including a history of losses, competition, and potential delays. The sentiment is cautiously optimistic but with considerable uncertainty.

Positives

• The offering provides flexibility for investors with the option to purchase either standard units or pre-funded units.
• The company intends to use the proceeds for general corporate purposes, including working capital and investments, which could support growth.
• The company plans to repay $4,174,658 in outstanding senior notes, which could improve its financial position.

Negatives

• There is no established trading market for the units, pre-funded units, warrants, or pre-funded warrants.
• The public offering price may be at a discount to the current market price at the time of pricing.
• The company has a history of losses and has not generated significant revenue from syringe sales to date.

Risks

• The company has a limited operating history and may not succeed.
• The company may not be able to raise capital as needed to develop products or maintain operations.
• The company is subject to product liability risk.
• The company may encounter significant competition and may not be able to successfully compete.
• The company's common stock could be subject to extreme volatility.
• Purchasers in the offering will suffer immediate dilution.
• The company may not be able to maintain its listing on the Nasdaq Capital Market.

Future Outlook

The company intends to use the net proceeds from this offering for working capital and other general corporate purposes and to repay outstanding debt.

Industry Context

The medical device industry is competitive, with many companies offering safety syringes. Sharps Technology aims to compete based on healthcare worker and patient safety, product performance, and quality, highlighting its ultra-low waste and passive safety features.

Comparison to Industry Standards

• The company anticipates competition from major players like Retractable Technologies, Inc., Becton, Dickinson & Company, Medtronic Minimally Invasive Therapies, Terumo Medical Corp., Smiths Medical, and B Braun.
• These competitors have considerably more financial resources than Sharps Technology.
• Sharps Technology aims to differentiate itself through its patented safety syringes, which are designed to be ultra-low waste and have both passive and active safety features.
• The company's Sharps Provensa syringe is FDA-cleared for subcutaneous and intramuscular injections, which is a standard regulatory hurdle for medical devices in this sector.
• The company's Securgard and Sologard products are also FDA and WHO approved, with Safegard carrying the European CE Mark, indicating compliance with international standards.

Legal Proceedings

• Barry Berler commenced a lawsuit against the Company in the United States District Court for the Eastern District of New York.
• Barry Berler filed a demand for arbitration and statement of claim under the commercial arbitration rules of the American Arbitration Association.
• Plastomold Industries Ltd. commenced a lawsuit against the Company in the United States District Court for the Eastern District of New York.

Related Party Transactions

• As of December 31, 2023 and 2022, accounts payable and accrued liabilities include $32,974 and $105,667, respectively, payable to officers and directors of the Company.
• At September 30, 2024, accounts payable and accrued liabilities includes $152,500 payable to officers and directors of the Company.

Stakeholder Impact

• Shareholders will experience immediate dilution from the offering.
• Employees may benefit from the company's growth and stability if the offering is successful.
• Customers may benefit from the company's ability to scale production and offer its products.
• Suppliers may benefit from increased orders and business with the company.
• Creditors may benefit from the company's repayment of outstanding debt.

Next Steps

• The company intends to use the net proceeds from this offering for working capital and other general corporate purposes and to repay outstanding debt.
• The company will seek stockholder approval for the warrants to be exercisable.
• The company will continue to work with Roncadelle for product introductions and execution of the Agreement for future sales.
• The company will continue to work towards a further amendment of the Asset Purchase Agreement with Nephron and InjectEZ, LLC.

Key Dates

Keywords

public offering, units, common stock, warrants, pre-funded warrants, medical device, safety syringes, capital raise, working capital, senior notes